Abstract
We investigated the long-term efficacy and tolerability of Levetiracetam as add-on therapy in refractory partial epilepsy. 160 patients (76 M) were enrolled; during three months before Levetiracetam was started seizure monthly frequency was 9.3+13.4 (range 0.7-94); during last three months in the observational period the seiizure frequency was 5.8+12.16 (range 0-86.6) (p <0.001). 40 (28%) patients were seizure free, 42 (30%) responders, 42 (30%) immodified and 18 (12%) patients were worsened. After 1 year 99 (71%) patients were till in the study. 22 (14%) patients withdrew the Levetiracetam because of adverse effects most commonly nervousness. This study confirm that the effectiveness of Levetiracetam in refractory partial epilepsy is maintened in the long period.
| Original language | Italian |
|---|---|
| Pages (from-to) | 195-197 |
| Number of pages | 3 |
| Journal | Bollettino - Lega Italiana contro l'Epilessia |
| Issue number | 125-126 |
| Publication status | Published - Jul 2004 |
Fingerprint
ASJC Scopus subject areas
- Clinical Neurology
Cite this
Studio prospettico in aperto sull'efficacia e la tollerabilità a lungo termine del Levetiracetam corne terapia aggiuntiva in pazienti con epilessia parziale farmacoresistente. / La Neve, A.; Boero, G.; Stuppiello, M.; Papantonio, A.; Specchio, N.; D'Alessandro, P.; De Palo, A.; De Agazio, G.; Plantamura, M.; Santosabato, M.; Francavilla, T.; Ottaviano, S.; Specchio, L. M.
In: Bollettino - Lega Italiana contro l'Epilessia, No. 125-126, 07.2004, p. 195-197.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Studio prospettico in aperto sull'efficacia e la tollerabilità a lungo termine del Levetiracetam corne terapia aggiuntiva in pazienti con epilessia parziale farmacoresistente
AU - La Neve, A.
AU - Boero, G.
AU - Stuppiello, M.
AU - Papantonio, A.
AU - Specchio, N.
AU - D'Alessandro, P.
AU - De Palo, A.
AU - De Agazio, G.
AU - Plantamura, M.
AU - Santosabato, M.
AU - Francavilla, T.
AU - Ottaviano, S.
AU - Specchio, L. M.
PY - 2004/7
Y1 - 2004/7
N2 - We investigated the long-term efficacy and tolerability of Levetiracetam as add-on therapy in refractory partial epilepsy. 160 patients (76 M) were enrolled; during three months before Levetiracetam was started seizure monthly frequency was 9.3+13.4 (range 0.7-94); during last three months in the observational period the seiizure frequency was 5.8+12.16 (range 0-86.6) (p <0.001). 40 (28%) patients were seizure free, 42 (30%) responders, 42 (30%) immodified and 18 (12%) patients were worsened. After 1 year 99 (71%) patients were till in the study. 22 (14%) patients withdrew the Levetiracetam because of adverse effects most commonly nervousness. This study confirm that the effectiveness of Levetiracetam in refractory partial epilepsy is maintened in the long period.
AB - We investigated the long-term efficacy and tolerability of Levetiracetam as add-on therapy in refractory partial epilepsy. 160 patients (76 M) were enrolled; during three months before Levetiracetam was started seizure monthly frequency was 9.3+13.4 (range 0.7-94); during last three months in the observational period the seiizure frequency was 5.8+12.16 (range 0-86.6) (p <0.001). 40 (28%) patients were seizure free, 42 (30%) responders, 42 (30%) immodified and 18 (12%) patients were worsened. After 1 year 99 (71%) patients were till in the study. 22 (14%) patients withdrew the Levetiracetam because of adverse effects most commonly nervousness. This study confirm that the effectiveness of Levetiracetam in refractory partial epilepsy is maintened in the long period.
KW - Levetiracetam
KW - Long-term Efficacy
KW - Refractory Partial Epilepsy
UR - http://www.scopus.com/inward/record.url?scp=22944437809&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=22944437809&partnerID=8YFLogxK
M3 - Articolo
AN - SCOPUS:22944437809
SP - 195
EP - 197
JO - Bollettino - Lega Italiana contro l'Epilessia
JF - Bollettino - Lega Italiana contro l'Epilessia
SN - 0394-560X
IS - 125-126
ER -